You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1664 Results
Regimen
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - (Neo)adjuvant Resectable Macroscopic Stage III Melanoma
New Drug Funding Program
    Nivolumab plus Ipilimumab - (Neo)adjuvant Resectable Macroscopic Stage III Melanoma
May 2025
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Updated
Jul 2025
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma
New Drug Funding Program
    Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma
Updated
Jul 2025
Regimen
Intent: Adjuvant
Updated
Jul 2025
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - Advanced Malignant Pleural Mesothelioma
New Drug Funding Program
    Nivolumab plus Ipilimumab - Advanced Malignant Pleural Mesothelioma
Updated
Jul 2025
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Mar 2023
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Nov 2024
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Nov 2024
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Intent: Palliative
Oct 2024
Regimen
Cancer Type:
Skin, 
Merkel Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Avelumab - Metastatic Merkel Cell Carcinoma
Jan 2025
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Adjuvant
Apr 2025
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Adjuvant, Curative, Palliative
May 2025

Pages